Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02154490
Recruitment Status : Completed
First Posted : June 3, 2014
Last Update Posted : April 27, 2022
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group